# OnCo record horizon-breast01 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/horizon-breast01/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "horizon-breast01", "NCT05424835" ;
  schema:name "HORIZON-Breast01"@en ;
  schema:description "A Chinese HER2 ADC cut the risk of progression by nearly 80% versus a pill-plus-chemotherapy standard, matching the scale of Enhertu's results."@en ;
  schema:url <https://onco.cc/trials/horizon-breast01/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05424835> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2022-08-04" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-rezetecan/>, <https://onco.cc/drugs/pyrotinib/> ;
  onco:companies <https://onco.cc/companies/hengrui/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-horizon-breast01-lancet-oncol-2026/> .